CCSN Director Elaine Dean was interviewed by CTV News about the results of the ATLAS (Adjuvant Tamoxifen — Longer Against Shorter) study announced at the San Antonio Breast Cancer Symposium. This study found that ten years of adjuvant treatment with tamoxifen provided women with estrogen receptor-positive breast cancer greater protection against late recurrence and death from breast cancer compared with the current standard of five years of tamoxifen.
The interview aired on CTV National News last evening, and can be viewed at http://www.ctvnews.ca/video?